Core Insights - Summit Therapeutics is a mission-driven organization focused on making a significant difference for cancer patients [1] - The company is currently developing ivonescimab, a PD-1 VEGF bispecific antibody, as part of its strategic vision [1][2] Company Overview - Summit Therapeutics is led by co-CEOs Bob Duggan and Maky Zanganeh, who have extensive experience in biotechnology and the healthcare sector [1] - The company's mission emphasizes improving patient outcomes in cancer treatment [1] Product Development - Ivonescimab is engineered to enhance previously established efficacy in cancer treatment [2]